Reference Interval:
| Test Number
| Components
| Reference Interval
| | | Acetylcholine Receptor Binding Antibody
| Negative: 0.0-0.4 nmol/L
Positive: 0.5 nmol/L or greater
| | | Acetylcholine Receptor Blocking Antibody
| Negative: 0-15% blocking
Indeterminate: 16-24% blocking
Positive: 25% or greater blocking
| | | Acetylcholine Receptor Modulating Antibody
| Negative: 0-20% modulation
Indeterminate: 21-25% modulation
Positive: 26% or greater modulation
| |
|
| Interpretive Data: |
Approximately 85-90% of patients with myasthenia gravis (MG) express antibodies to the acetylcholine receptor (AChR), which can be divided into binding, blocking, and modulating antibody. Binding antibody can activate complement and lead to loss of AChR. Blocking antibody may impair AChR binding to the receptor, leading to poor muscle contraction. Modulating antibody causes receptor endocytosis resulting in loss of AChR expression, which correlates most closely with clinical severity of disease. Approximately 10-15% of individuals with confirmed myasthenia gravis have no measurable binding, blocking, or modulating antibody.
Please refer to Statement B in the Compliance Statements section in the front of the Laboratory Test Directory.
|
| CPT Code(s): |
83519 ACHR Binding Ab; 83519 ACHR Blocking Ab; 83519 ACHR Modulating Ab
|
|